Intravenous ibuprofen versus sodium valproate in acute migraine attacks in the emergency department: A randomized clinical trial
- PMID: 35313227
- DOI: 10.1016/j.ajem.2022.02.046
Intravenous ibuprofen versus sodium valproate in acute migraine attacks in the emergency department: A randomized clinical trial
Abstract
Objective: Sodium valproate and ibuprofen are drugs with known efficacy in the treatment of headache associated with acute migraine attacks. In this study, our aim was to compare the efficacy of these two drugs in the treatment of acute migraine attacks when administered as a single intravenous (IV) dose in the emergency department.
Materials and method: This study was designed as a prospective, randomized controlled, double-blinded study and included patients aged 18 to 65 years who presented to the emergency department with acute headache and met the criteria of 'migraine without aura' according to the International Classification of Headache Disorders. The patients were randomized into two groups and given a single dose of 800 mg sodium valproate or 800 mg ibuprofen in 150 mL of normal saline by IV infusion over five minutes. Changes in pain levels were assessed using the Numerical Rating Scale (NRS) for pain over a two-hour period.
Results: Ninety-nine patients (49 patients in the sodium valproate group and 50 in the ibuprofen group) completed the trial, and their data were included in the statistical analysis. The mean decrease in the post-treatment delta NRS values was statistically significantly higher in the sodium valproate group than in the ibuprofen group. The mean differences were 1.69 [confidence interval (CI): 1.02-2.37, p<0.001], the mean difference between N0 and N2 was 3.61 (CI: 2.96-4.26, p < 0.001), the mean difference between N0 and N3 was 4.11 (CI: 3.54-4.67, p < 0.001), and the mean difference between N0 and N4 was 3.92 (CI: 3.67-4.46, p < 0.001). The number of patients who achieved the primary endpoint of pain relief was significantly higher in the sodium valproate group than in the ibuprofen group (p < 0.001). According to the Kaplan-Meier analysis showing the rates of reaching the targeted endpoint, there was a significant difference in the efficacy of the two-treatment group (χ2 = 79.98, CI: 80.35-99.65; p = 0.000).
Keywords: Ibuprofen; Migraine; Migraine without aura; Sodium valproate.
Copyright © 2022 Elsevier Inc. All rights reserved.
Comment in
-
Intravenous ibuprofen versus sodium valproate in acute migraine attacks in the emergency department.Am J Emerg Med. 2022 Dec;62:123. doi: 10.1016/j.ajem.2022.08.033. Epub 2022 Aug 18. Am J Emerg Med. 2022. PMID: 36031482 No abstract available.
-
Intravenous ibuprofen versus sodium valproate in acute migraine attacks in the emergency department.Am J Emerg Med. 2023 Mar;65:190. doi: 10.1016/j.ajem.2022.09.009. Epub 2022 Sep 15. Am J Emerg Med. 2023. PMID: 36599776 No abstract available.
Similar articles
-
Effect of intravenous sodium valproate vs dexamethasone on acute migraine headache: a double blind randomized clinical trial.PLoS One. 2015 Mar 20;10(3):e0120229. doi: 10.1371/journal.pone.0120229. eCollection 2015. PLoS One. 2015. PMID: 25793707 Free PMC article. Clinical Trial.
-
Intravenous sodium valproate versus prochlorperazine for the emergency department treatment of acute migraine headaches: a prospective, randomized, double-blind trial.Ann Emerg Med. 2003 Jun;41(6):847-53. doi: 10.1067/mem.2003.195. Ann Emerg Med. 2003. PMID: 12764341 Clinical Trial.
-
Intravenous ibuprofen versus sodium valproate in acute migraine attacks in the emergency department.Am J Emerg Med. 2022 Dec;62:123. doi: 10.1016/j.ajem.2022.08.033. Epub 2022 Aug 18. Am J Emerg Med. 2022. PMID: 36031482 No abstract available.
-
Intravenous sodium valproate for acute migraine in the emergency department: A meta-analysis.Acta Neurol Scand. 2020 Dec;142(6):521-530. doi: 10.1111/ane.13325. Epub 2020 Aug 25. Acta Neurol Scand. 2020. PMID: 32740903
-
Sodium Valproate Versus Dopamine Antagonists for Acute Migraine in the Emergency Department: A Systematic Review.Can J Neurol Sci. 2022 Sep;49(5):688-695. doi: 10.1017/cjn.2021.195. Epub 2021 Aug 12. Can J Neurol Sci. 2022. PMID: 34382533
Cited by
-
Advancements in Valproate Therapy for Seizures, Migraines, and Bipolar Disorders.Med Princ Pract. 2025;34(4):301-315. doi: 10.1159/000543555. Epub 2025 Jan 17. Med Princ Pract. 2025. PMID: 39827871 Free PMC article. Review.
-
Comparison of analgesic efficacy of ibuprofen and dexketoprofen in pain management of long bone fractures: a prospective, randomized, double-blind study.Eur J Trauma Emerg Surg. 2024 Aug;50(4):1791-1798. doi: 10.1007/s00068-024-02515-w. Epub 2024 Apr 23. Eur J Trauma Emerg Surg. 2024. PMID: 38653816 Clinical Trial.
-
Saudi clinical practice guidelines for the treatment and prevention of migraine headache.Neurosciences (Riyadh). 2025 Apr;30(2):77-91. doi: 10.17712/nsj.2025.2.20240097. Neurosciences (Riyadh). 2025. PMID: 40199542 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous